Dear Patients, Family, and Friends, 

The SOLA team has been working diligently on creating effective gene-therapies for patients with neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Huntington's disease (HD).  Our technology, we call it "JUMP70," is designed to selectively reduce the abnormal disease-causing proteins that form toxic clumps in the neuron cells of patients with these diseases. For example, one of our clinical candidates "SOL-257" targets pathogenic TDP-43 to repair the specific problem that causes ALS, and the data indicate SOL-257 could delay disease progression and prolong their lifespan as seen in our experiments with ALS model animal.  In addition, SOLA currently has nine more clinical candidates with JUMP70 technology to target other challenging diseases; most are still in the preclinical stage of development.  

SOLA is fortunate to work together with distinguished researchers, medical doctors, foundations, collaborators, and investors to make this technology available for you and your loved one in need at the earliest possible time.  

Sincerely,

SOLA Team